Categories
Change Password!
Reset Password!
Zuranolone 30 mg offers rapid, well-tolerated relief for depression, with sustained benefits and minimal adverse effects.
A newly FDA-approved neurosteroid- Zuranolone proved to have impressive tolerability and safety for the treatment of depression, the findings of a systematic review and meta-analysis published in the ‘Psychopharmacology’ journal exposed. A comprehensive analysis of eight clinical trials, conducted until September 2023 by Aya M. Fayoud et al., assessed Zuranolone's efficacy and safety.
The results indicated that both the 30 mg and 50 mg doses considerably reduced depression symptoms, with improvements in the Hamilton Depression Rating Scale (HAM-D) scores by over 50% after just 15 days. In particular, the 30 mg dose showed substantial improvements, with a relative risk (RR) of 1.82 (95% Confidence Interval [1.44, 2.31], p < 0.0001) after 15 days, and continued benefits through 45 days.
Regarding safety, Zuranolone's side effects were comparable to those of a placebo, with no major differences in drug discontinuation rates or common adverse events like headaches. Notably, the 30 mg dose was associated with fewer headaches, further highlighting its favorable safety profile.
Psychopharmacology
The efficacy and safety of Zuranolone for treatment of depression: A systematic review and meta-analysis
Aya M. Fayoud et al.
Comments (0)